Kalali Behnam, Formichella Luca, Gerhard Markus
Institute of Medical Microbiology, Immunology and Hygiene, TU-Munich, Troger Str.30, 81675 Munich, Germany.
ImevaX GmbH, Grillparzer Str.18, 81675 Munich, Germany.
Diseases. 2015 Jun 29;3(3):122-135. doi: 10.3390/diseases3030122.
Since the first evidence demonstrating the dramatically high incidence of infection and the subsequent medical challenges it incurs, health management of infection has been a high priority for health authorities worldwide. Despite a decreasing rate of infection in western countries, prevalence of infection in developing and in some industrial countries is still very high. Whereas treatment and vaccination against is a contemporary issue in medical communities, selective treatment and prior high-throughput screening of the subject population is a major concern of health organizations. So far, diagnostic tests are either elaborative and require relatively advanced medical care infrastructure or they do not fulfill the criteria recommended by the Maastricht IV/Florence consensus report. In this review, in light of recent scientific studies, we highlight current and possible future approaches for the diagnosis of . We point out that novel non-invasive tests may not only cover the requirements of gold standard methods in detection but also offer the potential for risk stratification of infection in a high throughput manner.
自从首次有证据表明感染发生率极高且随之带来医学挑战以来,感染的健康管理一直是全球卫生当局的首要任务。尽管西方国家的感染率在下降,但发展中国家和一些工业化国家的感染患病率仍然很高。虽然针对[疾病名称]的治疗和疫苗接种是医学界的当代问题,但对目标人群进行选择性治疗和事先的高通量筛查是卫生组织的主要关切。到目前为止,诊断测试要么复杂且需要相对先进的医疗基础设施,要么不符合马斯特里赫特IV/佛罗伦萨共识报告推荐的标准。在本综述中,鉴于最近的科学研究,我们强调了目前和未来可能用于[疾病名称]诊断的方法。我们指出,新型非侵入性测试不仅可能满足[疾病名称]检测中黄金标准方法的要求,还可能具有以高通量方式对感染进行风险分层的潜力。